SEC Form 3 FORM 3

UNITED STATES SECURITIES AND EXCHANGE

COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

3235-OMB Number: 0104

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Adler Eric</u>			Requiring (Month/Da	2. Date of Event Requiring Statement (Month/Day/Year) 11/02/2023 3. Issuer Name and Ticker or Trading Symbol Lexeo Therapeutics, Inc. [LXEO]					
(Last) (First) (Middle) C/O LEXEO THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, FLOOR 6			_		4. Relationship of Reporting Person(s Issuer (Check all applicable) Director 10% C X Officer (give Other title below) below) Chief Scientific Officer		wner (specify	If Amendment, Date of Original lied (Month/Day/Year)	
NEW YORK	NY	10010	_					Reporting F	
(City)	(State)	(Zip)							
		٦	āble I - No	n-Derivat	ive Securities Benef	icially Ov	vned		
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Instr. 4)	Form: D (D) or Ir	Dwnership rm: Direct or Indirect (Instr. 5)4. Nature of Indirect Beneficial Ownership (Instr. 5)		
		(e.			e Securities Benefici nts, options, conver				
1. Title of De	erivative Secur	•		IIS, Warra		tible sec	4. Conversion Or Exercise	se Form:	6. Nature of Indirect Beneficial Ownership (Instr.
1. Title of De	erivative Securi	•	9., puts, ca 2. Date Exerc Expiration D	IIS, Warra	nts, options, conver 3. Title and Amount of S Underlying Derivative Se	tible sec	4. Conversio	on Ownership se Form: Direct (D)	Indirect Beneficial
	erivative Securi	ity (Instr. 4)	g., puts, ca 2. Date Exerc Expiration Da (Month/Day/N Date	IIS, warra cisable and ate Year) Expiration	nts, options, conver 3. Title and Amount of S Underlying Derivative Se (Instr. 4)	tible sec ecurities ecurity Amount or Number of	4. Conversion or Exercise Price of Derivative	on Ownership Se Form: Direct (D) or Indirect	Indirect Beneficial Ownership (Instr.
Employee buy)		ity (Instr. 4) (right to	g., puts, ca 2. Date Exerc Expiration D (Month/Day/) Date Exercisable	IIS, WARRA	nts, options, conver 3. Title and Amount of S Underlying Derivative Se (Instr. 4) Title	tible sect ecurities ecurity Amount or Number of Shares	4. Conversic or Exercis Price of Derivative Security	on Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	Indirect Beneficial Ownership (Instr.
Employee buy) Employee buy)	Stock Option	(right to (right to	g., puts, ca 2. Date Exerc Expiration D: (Month/Day/V Date Exercisable	IIS, WARRA cisable and ate Year) Expiration Date 11/03/2031	nts, options, conver 3. Title and Amount of S Underlying Derivative Se (Instr. 4) Title Common Stock	tible sect ecurities ecurity Amount or Number of Shares 39,284	4. Conversion or Exercise Price of Derivative Security 4.87	Direct (D) or Indirect (I) (Instr. 5)	Indirect Beneficial Ownership (Instr.

Explanation of Responses:

1. 1/48th of the shares underlying the option vested or shall vest in monthly installments commencing on August 16, 2021, subject to the Reporting Person's continuous service. 2. Fully vested and exercisable.

3. 25% of the shares underlying the option vested on August 1, 2023, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

4. 25% of the shares underlying the option shall vest on August 22, 2024, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

/s/ Jenny Robertson,

Attorney-in-Fact ** Signature of Reporting Person

11/02/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Exhibit 24

POWER OF ATTORNEY

(For Executing Form ID and Forms 3, 4 and 5)

Know all by these presents, that the undersigned hereby constitutes and appoints each of R. Nolan Townsend and Jenny Robertson of Lexeo Therapeutics, Inc. (the "Company") and Dayne Brown and Jason Minio of Cooley LLP, signing individually, the undersigned's true and lawful attorneys-in fact and agents to:

(1) Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC"), a Form ID and Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in connection therewith) in accordance with Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of the Company;

(2) Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Form ID and Forms 3, 4 or 5 (including amendments thereto and joint filing agreements in connection therewith) and file such forms with the SEC and any stock exchange, self-regulatory association or any similar authority; and

(3) Take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney in fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney in fact, or such attorney in fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming (nor is the Company assuming) any of the undersigned Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or employed by or a partner at Cooley LLP or another law firm representing the Company, as applicable.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below.

Date: 9/21/2023 /s/ Eric Adler Eric Adler